11 results about "Cord blood" patented technology

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of umbilical cord blood plasma-derived extracellular vesicles and related bioactive molecules thereof in treatment of Alzheimer's disease. Specifically, the application isolates extracellular vesicles (UCBP-sEVs) from umbilical cord blood plasma, which has the effect of improving Alzheimer's disease. Further research finds that high enrichment of miR-16-2-3p therein is a key molecule for mediating treatment of Alzheimer's disease. miR-16-2-3p targets and inhibits expression of ROCK2, reduces phosphorylation level of TFEB and promotes nuclear translocation of the same, activates microglial autophagy-lysosome pathway, and thus promotes phagocytosis and degradation of intracerebral beta amyloid, and therefore has good practical application value.

The application discloses a general allogeneic CAR-NK cell preparation and application thereof, and belongs to the technical field of cell immunotherapy biological preparations. The preparation comprises pre-activated modified allogeneic CAR-NK cells, a composite protective agent system and a medicinal buffer, and is prepared from umbilical cord blood-derived NK cells through non-integrated CAR lentivirus transfection, cytokine combination pre-activation and liposome membrane anchoring HLA-G immune shielding modification. The composite protective agent system is created for the first time, and can simultaneously realize the functions of cryopreservation protection, in-vivo synergism and immunoregulation, and solve the defects of existing allogeneic CAR-NK preparations, such as dependence on gene editing, poor cryopreservation stability, high immunogenicity, short in-vivo survival time and insufficient anti-tumor activity, and can be used for preparing a therapeutic drug for CD19-positive hematological malignancies, and is suitable for industrialized development of "off-the-shelf" general cell treatment products.

The present application provides a functional cosmetic composition containing stem cell culture solution and a preparation method thereof, wherein the functional cosmetic composition contains, based on 100 parts by weight of stem cell culture solution from one source selected from the group consisting of human adipose-derived stem cells, bone marrow, umbilical cord blood, peripheral blood, and adipose tissue base, 30 to 40 parts by weight of purified water, 1 to 5 parts by weight of glycolic acid, 3 to 7 parts by weight of trehalose, 5 to 20 parts by weight of serine, 1 to 3 parts by weight of d-panthenol, 1 to 5 parts by weight of organic sulfur, 1 to 5 parts by weight of methionine liquid, 0.3 to 1 parts by weight of hemp seed oil, and 0.1 to 0.5 parts by weight of aromatic oil.

The application provides a healthy human umbilical cord blood-derived immortalized NK cell line SZ093 and a preparation method and application thereof. The healthy human umbilical cord blood-derived immortalized NK cell line SZ093 is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The healthy human umbilical cord blood-derived immortalized NK cell line SZ093 provided by the application can still maintain good proliferation ability and high survival rate in a long-time (more than 1 year) culture process, and has high killing ability to tumor cells.

The present application belongs to the technical field of cell separation, and particularly relates to a method for simultaneously separating hematopoietic stem cells and platelet-rich plasma from one portion of umbilical cord blood. The present application adopts two-step centrifugation to replace traditional multiple centrifugation separation, and has the advantages of simple operation, shortened time, reduced pollution risk, and the ability to simultaneously separate hematopoietic stem cells and platelet-rich plasma from one bag of umbilical cord blood, thereby avoiding waste of umbilical cord blood resources, and being particularly suitable for precious samples or clinical combined treatment.

The utility model relates to a multi-chamber cryopreservation box which comprises a box body 20, a box cover 10 and a multi-chamber freezing bag 30 used for cryopreservation, a plurality of separating strips 22 protruding towards the inner side of the box body are arranged on the bottom face 21 of the box body, and the separating strips 22 divide the box body 20 into a plurality of cryopreservation cells 23 on the bottom face 21 of the box body. The umbilical cord blood sample cryopreservation box has the advantages that the separating strips are arranged at the bottom of the cryopreservation box and divide the cryopreservation box into a plurality of cryopreservation grids, each freezing chamber of the multi-chamber freezing bag can be stably kept in one cryopreservation grid, the multi-chamber freezing bag is prevented from sliding in the cryopreservation box, and cryopreservation protection safety of umbilical cord blood samples can be effectively guaranteed; an observation opening is formed corresponding to each cryopreservation grid, and a light hole is formed opposite to the observation opening, so that whether a freezing chamber exists in the cryopreservation grid or not can be clearly seen, and the cryopreservation management of the umbilical cord blood sample is facilitated.

The present invention relates to the use of compositions comprising specific exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) in the prevention and treatment of fibrotic disorders such as fibrotic skin and lung injuries. The exosome compositions of the invention present activity in skin fibrosis and in lung diseases. Moreover, these compositions are also effective in reverting or preventing disease-associated parameters, such of lung diseases, proving its action against respiratory disorders with an inflammatory component, particularly when mediated by macrophages and / or T-cells. Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, dermo-cosmetics, research and development in cellular biology and appliances thereof.

The application belongs to the technical field of biology and particularly relates to a method for in-vitro rotation culture of embryos. The method places the embryos in embryo culture solution for culture, wherein the embryo culture solution comprises fresh rat serum, antibiotics, ascorbic acid or derivatives thereof, pyruvic acid or salts thereof, glutamine, buffer salt and optionally glucose; the embryo culture solution does not contain human umbilical cord blood serum; the use of human umbilical cord blood serum is avoided, so that the embryo rotation culture system can be quickly popularized; and further limitation is made to the use of fresh rat serum, adjustment of oxygen concentration at different periods, which can improve the proportion of embryos with continued blood flow in the yolk sac blood vessels at the E7.5+3 day period, realize the rapid blood flow in the yolk sac blood vessels of mouse embryos at the E7.5+5 day period, and complete the in-vitro culture process of mouse embryos from E7.5 to E7.5+6 day.

The present invention relates to a composition for disease-modifying treatment of osteoarthritis. More specifically, the present invention relates to a composition for treating osteoarthritis and a method for treating osteoarthritis by using same, the composition comprising human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and an acellular cartilage matrix.

Embodiments of this disclosure relate to methods and compositions relating to the optimization and selection of umbilical cord blood units for the production of immune cells, such as natural killer (NK) cells, for use in adoptive cell therapy. In certain embodiments, specific properties of an umbilical cord blood unit and / or the properties of cells obtained therefrom are analyzed. If a threshold measurement is met for one or more properties of the umbilical cord blood unit and / or the properties of cells obtained therefrom, the umbilical cord blood unit is used as a source for the production of immune cells. Specific properties to be measured include, for example, the viability of umbilical cord blood cells, the time from birth to cryopreservation of the umbilical cord blood unit, the total nucleated cell recovery rate, infant weight, infant sex, maternal age, gestational age, CD34-positive cell percentage, and / or nucleated red blood cell content. These properties may be determined before and / or after cryopreservation.

The application discloses a chimeric antigen receptor targeting CD180 and application thereof. Through flow cytometry, degranulation analysis experiment and detection of T cell secreted cytokines, it is proved that the T cell modified by the chimeric antigen receptor has a strong killing effect on acute myeloid leukemia cells expressing CD180, has no killing effect on cells not expressing CD180, effectively prevents off-target effect, and does not affect the colony formation ability of umbilical cord blood derived CD34 + hematopoietic stem / progenitor cells, and is safe. The chimeric antigen receptor CD180scFv-CD8alpha-4-1BB-CD3zeta of the application can be used for treating CD180 positive blood tumors.